Compare ESCA & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESCA | EDIT |
|---|---|---|
| Founded | 1922 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 249.4M | 206.0M |
| IPO Year | 1995 | 2016 |
| Metric | ESCA | EDIT |
|---|---|---|
| Price | $17.62 | $2.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $4.92 |
| AVG Volume (30 Days) | 45.1K | ★ 1.4M |
| Earning Date | 05-04-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.47% | N/A |
| EPS Growth | 6.45 | ★ 37.50 |
| EPS | ★ 0.99 | N/A |
| Revenue | ★ $180,541,000.00 | $31,937,000.00 |
| Revenue This Year | $4.15 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.77 | ★ N/A |
| Revenue Growth | 2.71 | ★ 132.64 |
| 52 Week Low | $11.41 | $1.18 |
| 52 Week High | $18.61 | $4.54 |
| Indicator | ESCA | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 57.19 | 70.86 |
| Support Level | $16.77 | $2.42 |
| Resistance Level | $18.53 | $3.17 |
| Average True Range (ATR) | 0.76 | 0.18 |
| MACD | -0.12 | 0.04 |
| Stochastic Oscillator | 51.63 | 98.15 |
Escalade Inc manufactures and distributes sporting goods for a varied range of activities. These sports include archery, table tennis, basketball goals, trampoline, play systems, fitness, game tables like hockey and soccer, billiards, darting, and other outdoor games. These products are sold under the brand names like Goalrilla, Goalsetter, Woodplay, Silverback, Nodor, Rage, Child Life, among others. The geographic segments in which the company operates are the United States, Canada, Australia, and Other regions.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.